Leading Biosciences

Leading BioSciences is advancing a novel therapeutic to address conditions that result from the breakdown of the intestinal mucosal barrier. Now in advanced clinical testing, LB1148 is designed to prevent postoperative ileus and surgical adhesions, reduce complications from cardiovascular surgery and stop multiple-organ failure from acute shock.